Metabolic
Survodutide
Also known as: BI 456906 · Glucagon/GLP-1 dual agonist
Metabolic & GLP-1 In stock Box of 10 vials 1 reference
Glucagon / GLP-1 dual agonist in phase 3 for obesity and MASH.
Available sizes
| SKU | Per vial | Pack | |
|---|---|---|---|
| SUR10 | 10 mg | 10 vials / box |
Order Survodutide
Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.
Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.
Survodutide is a dual agonist of the glucagon and GLP-1 receptors developed for obesity and metabolic-dysfunction-associated steatohepatitis (MASH). Its glucagon-receptor component is intended to drive hepatic fat oxidation.
In a 46-week phase 2 trial (n = 387), survodutide 4.8 mg produced a mean weight change of −14.9% versus −2.8% with placebo, with dose-dependent responses from 0.6 mg upward 1.
At a glance
- Glucagon + GLP-1 receptor dual agonism
- Phase 2: −14.9% at 46 weeks (4.8 mg)
- 10 mg vials
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
- Form
- Lyophilized powder
- Purity
- HPLC-verified — Certificate of Analysis available on request
- Pack size
- Box of 10 vials
- Storage
- Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.
- CAS No.
- 2271296-41-6
Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.
- le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173.
Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.
Related
Often ordered together
Metabolic
Retatrutide
GGG triple agonist · LY3437943
Triple GIP / GLP-1 / glucagon receptor agonist — the next generation of incretin research.
5 mg10 mg15 mg20 mg30 mg +4
Metabolic
Tirzepatide
GIP/GLP-1 dual agonist · LY3298176
Dual GIP and GLP-1 receptor agonist with the deepest weight-change effect of any approved incretin.
5 mg10 mg15 mg20 mg30 mg +5